Psychedelics

Friday Jun 10, 2022 - 3:01 pm

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leveraging Profitable Model to Scale Best-in-Class Care Directly to Patients

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, owns and operates an assortment of related businesses and is backed by a team of industry and cannabis veterans. The company’s mission is to provide education, research, high-quality products, and effective treatment options to the masses. “In a January interview, Delic CEO and Co-Founder Matt Stang explained that there are 51.5 million Americans who…

Friday Jun 10, 2022 - 10:25 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, received Institutional Review Board (“IRB”) approval to begin its planned phase 1/2a clinical trial. The trial, the first-in-human phase 1/2a trial evaluating CYBN’s proprietary deuterated psilocybin analog CYB003, is slated to begin in mid-2022.The study will evaluate CYB003 for the treatment of major depressive disorder (“MDD”). Cybin applied for IRB approval just…

Monday Jun 06, 2022 - 9:44 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Adelia Has Reached Milestone Achievements

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that Adelia Therapeutics Inc., its wholly owned subsidiary, has achieved significant milestones, which the company identified as Y2, Q2 (i), (vi), Y2, Q3 (ii), Year 2 Q4 (i) and Year 3 Q1 (i), (ii). These milestones are outlined in the Dec. 4, 2021, contribution agreement between Cybin and Adelia; the agreement…

Friday Jun 03, 2022 - 10:05 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses the company’s model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. Titled “Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment…

Thursday Jun 02, 2022 - 10:50 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will host a virtual Key Opinion Leader webinar from 11:00 a.m. to 12:00 p.m. ET on Thursday, June 9, 2022. The webinar will be moderated by Cybin’s Chief Executive Officer Doug Drysdale and will feature two leading experts for a discussion on the psychedelics landscape and…

Wednesday Jun 01, 2022 - 11:37 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Submits IND Application

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced that it has submitted an investigational new drug (“IND”) application with the U.S. Food and Drug Administration and Health Canada. The application is for the FDS-PEA and includes details of a planned phase 2 clinical trial of the substance for the treatment…

Wednesday Jun 01, 2022 - 10:26 am

InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Expanding Availability of First-of-Its-Kind Treatment – SPRAVATO(R)

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary Ketamine Wellness Centers (“KWC”) , the largest ketamine therapy provider in the U.S., has expanded the availability of SPRAVATO(R) to three new cities and increased the total number of clinics offering the FDA-approved esketamine nasal spray to six. According to the update, the KWC clinics in Minneapolis, Salt Lake City and Dallas now join the Houston,…

Tuesday May 31, 2022 - 1:52 pm

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Annual Filings

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has reported that, further to its news release dated May 16, 2022, the company has filed its annual financial statements, management’s discussion and analysis, and related certifications for the year ended Dec. 31, 2021, (collectively, the “annual filings”). Delic expects that the management cease trade order…

Tuesday May 31, 2022 - 11:41 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Files IND Application for Phase-2 Trial of FSD-PEA

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) and Health Canada. The IND application details a planned phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder.…

Tuesday May 31, 2022 - 10:22 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Major Step in Advancement of CYB003 for the Treatment of Major Depressive Disorder

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). According to the update, the IND is for Cybin’s phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”). “Following the…

Thursday May 26, 2022 - 2:49 pm

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Providing Scalable, Trusted, Accessible Network of Psychedelic Clinics

Delic Holdings (CSE: DELC) (OTCQB: DELCF) is moving to fill the gaps exposed by substantial pandemic-induced disruptions of mental health services. This is amid the World Health Organization’s statistics that COVID-19 has led to a 25% increase in the number of cases of anxiety and depression globally. To fulfill its mission to heal the mental health pandemic, Delic offers education, research, and high-quality products and…

Wednesday May 25, 2022 - 11:38 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Names New Independent Director to Board

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has appointed industry leader Chris Ntoumenopoulosto its board of directors. Ntoumenopoulos has deep and impressive experience in raising capital and corporate strategy, and his expertise is well-suited to support the company’s focus on advancing the delivery of psychedelic medicines. Currently managing director at 21…

Tuesday May 24, 2022 - 12:31 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Issuance of Circular, Incentive Plan and Granting of PSUs

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has issued a management information circular in respect of the annual general meeting of shareholders to be held on June 23, 2022. The circular is available on the company’s profile on SEDAR at www.SEDAR.com. In addition, to provide…

Monday May 23, 2022 - 1:39 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope to Patients Suffering from Alzheimer’s and Potentially Other Ailments

Silo Pharma (OTCQB: SILO) is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s and Parkinson’s disease. With more than 80% of Parkinson’s patients and 75% of Alzheimer’s patients experiencing dysphagia, difficulty or complete inability to swallow, last year, SILO entered into a joint venture with Zylö Therapeutics. Under the collaboration, the companies will explore an innovative technology – ZTI’s Z-pod transdermal…

Monday May 23, 2022 - 1:11 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners to Help Accelerate Regulatory Pathway of CYB003

Cybin (NYSE American: CYBN) (NEO: CYBN) is moving forward with its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003, which, previous research shows, has the potential to effectively treat major depressive disorder (“MDD”) with significant advantages over classic psilocybin. MDD impacts over 264 million people worldwide, 1/3 to 1/2 of whom demonstrate an inadequate response to antidepressant drug treatment. Against this backdrop, Cybin…

Thursday May 19, 2022 - 11:21 am

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Milestone in Psilocybin Study on Parkinson’s Patients

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that, in conjunction with the University of California San Francisco (“UCSF”), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of the study, researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of…

Wednesday May 18, 2022 - 11:01 am

InvestorNewsBreaks – Silo Pharma Inc. (SILO) CEO Featured in Bell2Bell Podcast Episode

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, and its founder and CEO Eric Weisblum are the center of attention in the most recent episode of the Bell2Bell Podcast. The Bell2Bell Podcast is designed to provide informative updates and exclusive interviews with executives operating in fast-moving industries. During the interview, hosted by Stuart Smith, Weisblum talks…

Wednesday May 18, 2022 - 10:28 am

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO to Share Expansion Strategy at H.C. Wainwright Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding participation of its CEO Matt Stang at the H.C. Wainwright Annual Global Life Sciences Conference taking place May 23-26, 2022, in Miami, Florida. The four-day event will feature keynote presentations, investor one-on-one meetings, networking opportunities and evening entertainment. At this year's conference,…

Tuesday May 17, 2022 - 12:40 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in May 18 NYSE Trading Bell Ceremony

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. The first psychedelics company to be listed on the NYSE, Cybin started trading on the exchange in August 2021. In addition, Cybin announced that management team members will be hosting in-person meetings…

Monday May 16, 2022 - 12:09 pm

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Issues Update on Default Status

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that it is providing a default status report; the report is being released in accordance with the alternative information guidelines set out in National Policy 12-203 — Management Cease Trade Orders (“NP 12-203”). According to the announcement, Delic is experiencing delays to its audit, which means…

Thursday May 12, 2022 - 12:23 pm

InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Enters New VA Partnership in Arizona

Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today announced a new partnership with the Veterans Administration (“VA”) in Arizona. Per the update, veterans suffering from treatment-resistant depression, PTSD and anxiety will have access to ketamine therapy at KWC Arizona clinics located in Phoenix, Tucson and Mesa - Gilbert…

Wednesday May 11, 2022 - 10:43 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright Global Investment Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference. The event is taking place May 23-26, 2022, at the Fontainebleau Miami Beach. Drysdale’s fireside chat will be webcast live at 12:30 p.m. ET on Wednesday, May 25. Interested…

Wednesday May 11, 2022 - 10:17 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million. This news and additional information about the company was featured in an InvestmentPitch Media video, available for viewing on InvestmentPitch and YouTube or by visiting www.InvestmentPitch.com and entering “FSD Pharma” in the…

Tuesday May 10, 2022 - 11:20 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Kernel Share Preliminary Results from Flow Feasibility Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its partner Kernel, are reporting preliminary data that confirm the ability of Kernel’s quantitative neuroimaging technology, Flow, to successfully measure neuro-effect of ketamine. Kernel is a leader in noninvasive neuroimaging. According to the announcement, results of a Cybin-sponsored feasibility study indicate that ketamine-induced changes in functional connectivity continued for several…

Tuesday May 10, 2022 - 10:32 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes CAD$16.4M Sale of Non-Core Assets

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the closing of the sale of the company’s former cannabis processing facility located in Cobourg, Ontario, Canada, for gross proceeds of CAD$16,400,000 in cash. “This is a major accomplishment and puts us in a good position going forward especially considering…

Friday May 06, 2022 - 2:16 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO), Frontage Laboratories to Collaborate in Pharmacokinetic Study

Silo Pharma (OTCQB: SILO) recently announced an agreement with Frontage Laboratories, a contract research organization, for an Investigational New Drug (“IND”)-enabling pharmacokinetic study. “Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” a recent article reads. “Frontage will study Silo’s central nervous system peptide, SPU-16, ’a potential new treatment for multiple sclerosis and other…

Thursday May 05, 2022 - 2:49 pm

InvestorNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article

Pasithea Therapeutics’ (NASDAQ: KTTA) CEO, Dr. Tiago Reis Marques, a psychiatrist at one of the top psychiatry centers in the world, a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London, was featured in a recent Forbes article. The piece, titled “You May Soon Find Mental Health Help from Psychedelic Drug-Assisted Psychotherapy in the Metaverse,” discusses record levels…

Thursday May 05, 2022 - 12:08 pm

InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Featured on Success Story Podcast

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its cofounder and CEO Matt Stang were spotlighted in a recent episode of The Success Story podcast. During the interview, Stang talked all things Delic, including a history of the company, his decision to pivot from a career in cannabis to psychedelics, and what he…

Thursday May 05, 2022 - 11:14 am

InvestorNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Preclinical Study Findings to Be Showcased at Global Event Focused on Psychedelic-Assisted Therapy

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentation at the “From Research to Reality” Global Summit on Psychedelic-Assisted Therapies and Medicines. The event is slated to take place from May 27-29, 2022, in Toronto, Canada. “It is…

Thursday Apr 28, 2022 - 2:41 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions in a commitment to transform the mental health treatment landscape. Through its proprietary deuterated process, Cybin is combining controllable drug-delivery systems with novel psychedelic molecules, thus creating patent-protected, commercially scalable drug candidates. “The company currently is moving three of these drug candidates…

Thursday Apr 28, 2022 - 9:48 am

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Participate in Upcoming Planet MicroCap Showcase

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, will be presenting at this year’s Planet MicroCap Showcase; the event is scheduled for May 3–5, 2022. During the showcase, Delic Holdings cofounder and CEO Matt Stang will be sharing an overview of the company, including details about business expectations and growth opportunities; his discussion, slated…

Wednesday Apr 27, 2022 - 1:39 pm

InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) KWC Committed to Providing Clinically-Backed, Accessible, Affordable Treatments

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, through its subsidiary and the largest ketamine therapy provider in the United States, Ketamine Wellness Centers (“KWC”), recently announced the expansion of its treatment options to include SPRAVATO(R) nasal spray for adults. The first FDA-approved ekestamine nasal spray for adults, SPRAVATO is made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive…

Friday Apr 22, 2022 - 10:16 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the KCSA Psychedelics Virtual Investor Conference. Drysdale’s presentation is slated to begin at 11:00 a.m. ET on Thursday, April 28, 2022, at the live, interactive online event designed to invite investors to ask the company questions in real-time. Interested parties…

Thursday Apr 21, 2022 - 12:39 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Advisory Board Appointments

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A),a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of David Allan and John McGraw, PhD, MSc, to the company’s advisory board. Allan is the 2017 recipient of the prestigious Julia Levy Award and will collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of…

Thursday Apr 21, 2022 - 12:27 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has partnered with Clinilabs Drug Development Corporation to work on its upcoming phase 1/2a clinical trial of CYB003. Clinilabs is a global, full-service contract research organization that has built a reputation for its expertise in central nervous system drug development. Derived from psilocybin, Cybin’s CYB003 is part of a family of…

Tuesday Apr 19, 2022 - 10:57 am

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Participate at Sequire Cannabis and Psychedelic Conference, Scottsdale Capital Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its co-founder and CEO Matt Stang will participate at the Sequire Cannabis and Psychedelic Conference and the Scottsdale Capital Event. Stang will present the company's performance and industry outlook and participate in one-on-one meetings with investors at the Sequire Cannabis and Psychedelic Conference.…

Thursday Apr 14, 2022 - 9:17 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), was spotlighted in an episode of the Power Play by the Market Herald. Cybin CEO Doug Drysdale talked with host Dave Jackson about the company’s recent positive results from its CYB004 pharmacokinetic study. The company announced that the study produced positive preclinical data demonstrating that when inhaled, Cybin’s deuterated dimethyltryptamine (“DMT”)…

Wednesday Apr 13, 2022 - 10:53 am

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Health Canada 56 Exemption for Research on Psychedelic Compounds

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its subsidiary Delic Labs have received a Health Canada 56 Research Exemption. The exemption gives approval for the company to conduct research and perform tests on several compounds, including MDMA, LSD, mescaline and 2C-B. The exemption also allows the lab to obtain psilocybin mushrooms from…

Wednesday Apr 13, 2022 - 10:32 am

InvestorNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (“DMT”) molecule, CYB004, delivered via inhalation. According to the announcement, inhaled CYB004 demonstrated significant advantages over both intravenous and inhaled DMT, including longer duration of action and improved bioavailability. The study also demonstrated that inhaled CYB004…

Friday Apr 08, 2022 - 1:31 pm

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Working to Capitalize on Psychedelics Therapeutics Market’s Growth

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. A recent article discusses the company’s efforts to lead the charge toward developing novel psychedelic and non-psychedelic molecules for medical use. “Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with…

InvestorNewsBreaks

NewsBreak Category: Psychedelics

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions